Damato Angela, De Marco Loredana, Serra Silvia, Larocca Mario, Arias Alicia Garcia, Rondini Ermanno, Pinto Carmine
Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Front Oncol. 2021 Jun 17;11:670415. doi: 10.3389/fonc.2021.670415. eCollection 2021.
Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies including non-small-cell lung cancer (NSCLC). Immune-mediated colitis is a known adverse effect of pembrolizumab which can lead to the treatment interruption, although not compromising the control of the oncological disease. Herein, we report the case of a 59-year-old woman on pembrolizumab for advanced NSCLC which developed a severe and persistent colitis treated with infliximab for several months following anti-PD-1 antibody discontinuation. This strategy resulted in an improvement but not complete recovery of the gastrointestinal toxicity despite revealed sustained response and control of the oncological disease with prolonged survival over 24 months.
帕博利珠单抗是一种程序性死亡受体-1（PD-1）抑制剂，已被批准用于治疗包括非小细胞肺癌（NSCLC）在内的多种恶性肿瘤。免疫介导的结肠炎是帕博利珠单抗已知的不良反应，虽不影响肿瘤疾病的控制，但可导致治疗中断。在此，我们报告一例59岁女性，因晚期NSCLC接受帕博利珠单抗治疗，在停用抗PD-1抗体后出现严重且持续的结肠炎，随后用英夫利昔单抗治疗数月。尽管肿瘤疾病持续缓解且得到控制，患者生存期延长超过24个月，但该策略仅使胃肠道毒性有所改善，并未完全恢复。
